Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission - PubMed (original) (raw)
. 2011 Apr 6;3(77):77ra29.
doi: 10.1126/scitranslmed.3001888.
Erin Kahle, Jairam R Lingappa, Robert W Coombs, Sinead Delany-Moretlwe, Edith Nakku-Joloba, Nelly R Mugo, Anna Wald, Lawrence Corey, Deborah Donnell, Mary S Campbell, James I Mullins, Connie Celum; Partners in Prevention HSV/HIV Transmission Study Team
Collaborators, Affiliations
- PMID: 21471433
- PMCID: PMC3087186
- DOI: 10.1126/scitranslmed.3001888
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission
Jared M Baeten et al. Sci Transl Med. 2011.
Abstract
High plasma HIV-1 RNA concentrations are associated with an increased risk of HIV-1 transmission. Although plasma and genital HIV-1 RNA concentrations are correlated, no study has evaluated the relationship between genital HIV-1 RNA and the risk of heterosexual HIV-1 transmission. In a prospective study of 2521 African HIV-1 serodiscordant couples, we assessed genital HIV-1 RNA quantity and HIV-1 transmission risk. HIV-1 transmission linkage was established within the partnership by viral sequence analysis. We tested endocervical samples from 1805 women, including 46 who transmitted HIV-1 to their partner, and semen samples from 716 men, including 32 who transmitted HIV-1 to their partner. There was a correlation between genital and plasma HIV-1 RNA concentrations: For endocervical swabs, Spearman's rank correlation coefficient ρ was 0.56, and for semen, ρ was 0.55. Each 1.0 log(10) increase in genital HIV-1 RNA was associated with a 2.20-fold (for endocervical swabs: 95% confidence interval, 1.60 to 3.04) and a 1.79-fold (for semen: 95% confidence interval, 1.30 to 2.47) increased risk of HIV-1 transmission. Genital HIV-1 RNA independently predicted HIV-1 transmission risk after adjusting for plasma HIV-1 quantity (hazard ratio, 1.67 for endocervical swabs and 1.68 for semen). Seven female-to-male and four male-to-female HIV-1 transmissions (incidence <1% per year) occurred from persons with undetectable genital HIV-1 RNA, but in all 11 cases, plasma HIV-1 RNA was detected. Thus, higher genital HIV-1 RNA concentrations are associated with greater risk of heterosexual HIV-1 transmission, and this effect was independent of plasma HIV-1 concentrations. These data suggest that HIV-1 RNA in genital secretions could be used as a marker of HIV-1 sexual transmission risk.
Conflict of interest statement
Competing interests: JRL is a member of the scientific advisory board of Prosetta Bioconformatics, Inc; CC has served as a paid scientific advisor to the research advisory boards of Merck and Gilead. The other authors report no competing interests.
Figures
Figure 1. Step-wise association between genital and plasma HIV-1 RNAquantity and HIV-1 transmission risk
HIV-1 transmission incidence detailed within categories of quantity of HIV-1 RNA for a) female-to-male and b) male-to-female HIV-1 transmission. HIV-1 incidence for each HIV-1 RNA quantity category (undetectable, <3, 3–4, 4–5, and ≥5 log10) is presented, for both genital HIV-1 RNA and plasma HIV-1 RNA. A step-wise relationship between HIV-1 quantity and HIV-1 transmission incidence was observed, for both genital and plasma HIV-1 quantity. The lower limit of quantification was 240 copies per mL for blood and seminal plasma and 240 copies/swab for endocervical samples.
Similar articles
- Comparisons of Human Immunodeficiency Virus Type 1 Envelope Variants in Blood and Genital Fluids near the Time of Male-to-Female Transmission.
Williams-Wietzikoski CA, Campbell MS, Payant R, Lam A, Zhao H, Huang H, Wald A, Stevens W, Gray G, Farquhar C, Rees H, Celum C, Mullins JI, Lingappa JR, Frenkel LM. Williams-Wietzikoski CA, et al. J Virol. 2019 Jun 14;93(13):e01769-18. doi: 10.1128/JVI.01769-18. Print 2019 Jul 1. J Virol. 2019. PMID: 30996101 Free PMC article. - Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples.
Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, Hong T, Donnell D, Celum C, Kapiga S, Delany S, Bukusi EA. Cohen CR, et al. PLoS Med. 2012;9(6):e1001251. doi: 10.1371/journal.pmed.1001251. Epub 2012 Jun 26. PLoS Med. 2012. PMID: 22745608 Free PMC article. - Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model.
Chakraborty H, Sen PK, Helms RW, Vernazza PL, Fiscus SA, Eron JJ, Patterson BK, Coombs RW, Krieger JN, Cohen MS. Chakraborty H, et al. AIDS. 2001 Mar 30;15(5):621-7. doi: 10.1097/00002030-200103300-00012. AIDS. 2001. PMID: 11317000 - [Sexual transmission of hepatitis C virus].
Ghosn J, Leruez-Ville M, Chaix ML. Ghosn J, et al. Presse Med. 2005 Aug 27;34(14):1034-8. doi: 10.1016/s0755-4982(05)84106-5. Presse Med. 2005. PMID: 16225259 Review. French. - Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis.
Powers KA, Poole C, Pettifor AE, Cohen MS. Powers KA, et al. Lancet Infect Dis. 2008 Sep;8(9):553-63. doi: 10.1016/S1473-3099(08)70156-7. Epub 2008 Aug 4. Lancet Infect Dis. 2008. PMID: 18684670 Free PMC article. Review.
Cited by
- Enhanced metabolic health and immune response with bictegravir/emtricitabine/TAF: Insights from a 96‑week retrospective study.
Spampinato S, Conti GN, Marino A, Raimondo V, Celesia BM, Pellicanò GF, Puci MV, Sotgiu G, Bruno R, Villari N, Mirabile A, Coco VAM, Paternò Raddusa MS, Pistarà E, Boscia V, Fisicaro V, Fiorenza G, Cacopardo B, Rullo EV, Nunnari G. Spampinato S, et al. Biomed Rep. 2024 Oct 2;21(6):179. doi: 10.3892/br.2024.1867. eCollection 2024 Dec. Biomed Rep. 2024. PMID: 39387001 Free PMC article. - Mosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primates.
Vanshylla K, Tolboom J, Stephenson KE, Feddes-de Boer K, Verwilligen A, Rosendahl Huber SK, Rutten L, Schuitemaker H, Zahn RC, Barouch DH, Wegmann F. Vanshylla K, et al. NPJ Vaccines. 2024 Sep 30;9(1):179. doi: 10.1038/s41541-024-00974-1. NPJ Vaccines. 2024. PMID: 39349488 Free PMC article. - Sexually transmitted infections and bacterial vaginosis among adolescent girls and young women in the early postpartum period: a cross-sectional study.
Govender V, Naidoo M, Moodley D. Govender V, et al. BMC Infect Dis. 2024 Sep 2;24(1):898. doi: 10.1186/s12879-024-09781-4. BMC Infect Dis. 2024. PMID: 39223449 Free PMC article. - Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.
Cafaro A, Schietroma I, Sernicola L, Belli R, Campagna M, Mancini F, Farcomeni S, Pavone-Cossut MR, Borsetti A, Monini P, Ensoli B. Cafaro A, et al. Int J Mol Sci. 2024 Jan 30;25(3):1704. doi: 10.3390/ijms25031704. Int J Mol Sci. 2024. PMID: 38338977 Free PMC article. Review. - HIV testing: the cornerstone of HIV prevention efforts in the USA.
Heffelfinger JD, Owen SM, Hendry RM, Lansky A. Heffelfinger JD, et al. Future Virol. 2011 Nov;6(11):10.2217/fvl.11.114. doi: 10.2217/fvl.11.114. Future Virol. 2011. PMID: 37965646 Free PMC article.
References
- Baeten JM, Overbaugh J. Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res. 2003;1:69–86. - PubMed
- Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 2003;17:455–480. - PubMed
- Anderson BL, Cu-Uvin S. Determinants of HIV shedding in the lower genital tract of women. Curr Infect Dis Rep. 2008;10:505–511. - PubMed
- Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH. Viral load and heterosexual transmission of human immunodeficiency virus type 1 Rakai Project Study Group. N Engl J Med. 2000;342:921–929. - PubMed
- Chuachoowong R, Shaffer N, Siriwasin W, Chaisilwattana P, Young NL, Mock PA, Chearskul S, Waranawat N, Chaowanachan T, Karon J, Simonds RJ, Mastro TD. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis. 2000;181:99–106. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AI038858/AI/NIAID NIH HHS/United States
- AI027757/AI/NIAID NIH HHS/United States
- U01 AI038858/AI/NIAID NIH HHS/United States
- P01 AI057005/AI/NIAID NIH HHS/United States
- P30 AI027757/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical